{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:03:24Z","timestamp":1789995804421,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41669-026-00668-5","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:36:09Z","timestamp":1787931369000},"page":"909-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Cost-Effectiveness Analysis for Treatments of Patients with Early Stage Huntington\u2019s Disease in the USA"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8878-5745","authenticated-orcid":false,"given":"Divya","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-9220","authenticated-orcid":false,"given":"Julia F.","family":"Slejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5545-7744","authenticated-orcid":false,"given":"Joseph M.","family":"Savitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-5780","authenticated-orcid":false,"given":"T. Joseph","family":"Mattingly II","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"668_CR1","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/mds.27653","volume":"34","author":"E Bruzelius","year":"2019","unstructured":"Bruzelius E, Scarpa J, Zhao Y, Basu S, Faghmous JH, Baum A. Huntington\u2019s disease in the United States: variation by demographic and socioeconomic factors. Mov Disord [Internet]. 2019;34:858\u201365. https:\/\/doi.org\/10.1002\/mds.27653.","journal-title":"Mov Disord [Internet]."},{"key":"668_CR2","unstructured":"European Huntington\u2019s Disease Network. About Huntington\u2019s disease [Internet]. ehdn.org.  https:\/\/ehdn.org\/about-hd\/. Accessed 15 Apr 2026."},{"key":"668_CR3","unstructured":"Huntington\u2019s Disease Society of America. Overview of Huntington\u2019s disease [Internet]. Hdsa.org. 2019. https:\/\/hdsa.org\/what-is-hd\/overview-of-huntingtons-disease\/"},{"key":"668_CR4","doi-asserted-by":"crossref","unstructured":"Yohrling G, Raimundo K, Crowell V, Lovecky D, Vetter L, Seeberger L. Prevalence of Huntington\u2019s disease in the US (954). Neurology [Internet]. 2020;94:1387. http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=emedx&NEWS=N&AN=631892123","DOI":"10.1212\/WNL.94.15_supplement.954"},{"key":"668_CR5","doi-asserted-by":"publisher","first-page":"117957352210925","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A. Current and possible future therapeutic options for Huntington\u2019s disease. J Cent Nerv Syst Dis [Internet]. 2022;14:11795735221092516. https:\/\/doi.org\/10.1177\/11795735221092517.","journal-title":"J Cent Nerv Syst Dis [Internet]."},{"key":"668_CR6","unstructured":"National Library of Medicine. A randomized, multicenter, double-blind, placebo-controlled, phase iii clinical study to evaluate the efficacy and safety of intrathecally administered RO7234292 (RG6042) in patients with manifest Huntington\u2019s disease [Internet]. clinicaltrials.gov. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761849"},{"key":"668_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, et al. Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol [Internet]. 2022;21:645\u201358.","journal-title":"Lancet Neurol [Internet]."},{"key":"668_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron [Internet]. 2012;74:1031\u201344. https:\/\/doi.org\/10.1016\/j.neuron.2012.05.009.","journal-title":"Neuron [Internet]."},{"key":"668_CR9","unstructured":"UniQure. UniQure announces second quarter 2022 financial results and highlights recent company progress [Internet]. GlobeNewswire News Room. 2022. https:\/\/www.globenewswire.com\/en\/news-release\/2022\/08\/08\/2493736\/0\/en\/uniQure-Announces-Second-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html"},{"key":"668_CR10","unstructured":"National Library of Medicine. A phase II, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, biomarkers, and efficacy of tominersen in individuals with prodromal and early manifest Huntington\u2019s disease [Internet]. clinicaltrials.gov. 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05686551"},{"key":"668_CR11","doi-asserted-by":"publisher","unstructured":"Divino V, DeKoven M, Warner JH, Giuliano J, Anderson KE, Langbehn D, et al. The direct medical costs of Huntington\u2019s disease by stage. A retrospective commercial and Medicaid claims data analysis. J Med Econ [Internet]. 2013;16:1043\u201350. https:\/\/doi.org\/10.3111\/13696998.2013.818545","DOI":"10.3111\/13696998.2013.818545"},{"key":"668_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000516767","volume":"55","author":"V Crowell","year":"2021","unstructured":"Crowell V, Houghton R, Tomar A, Fernandes T, Squitieri F. Modeling manifest Huntington\u2019s disease prevalence using diagnosed incidence and survival time. Neuroepidemiology [Internet]. 2021;55:361\u20138. https:\/\/doi.org\/10.1159\/000516767.","journal-title":"Neuroepidemiology [Internet]."},{"key":"668_CR13","unstructured":"Caron NS, Wright GEB, Hayden MR. Huntington disease. Seattle (WA); 1993."},{"key":"668_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/mds.28866","volume":"37","author":"A Mohan","year":"2022","unstructured":"Mohan A, Sun Z, Ghosh S, Li Y, Sathe S, Hu J, et al. A machine-learning derived Huntington\u2019s disease progression model: insights for clinical trial design. Mov Disord [Internet]. 2022;37:553\u201362. https:\/\/doi.org\/10.1002\/mds.28866.","journal-title":"Mov Disord [Internet]."},{"key":"668_CR15","doi-asserted-by":"publisher","unstructured":"Furr Stimming E, Sung V, Testa C, Kostyk S, Ross CA, Samii A, et al. J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I\/II clinical trial of AMT-130 (HD-genetrx-1) for early-stage Huntington\u2019s disease (HD). J Clin Ther [Internet]. 2022. https:\/\/doi.org\/10.1136\/jnnp-2022-ehdn.255","DOI":"10.1136\/jnnp-2022-ehdn.255"},{"key":"668_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s41669-024-00531-5","volume":"9","author":"D Patil","year":"2025","unstructured":"Patil D, Gorman EF, Mattingly TJ. Costs of illness for Huntington\u2019s disease: a systematic review. PharmacoEconomics Open [Internet]. 2025;9:5\u201313. https:\/\/doi.org\/10.1007\/s41669-024-00531-5.","journal-title":"PharmacoEconomics Open [Internet]."},{"key":"668_CR17","unstructured":"U.S. Bureau of Labor Statistics. Consumer Price Index for all urban consumers (CPI-U) [Internet]. data.bls.gov. 2024. https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM?output_view=data"},{"key":"668_CR18","unstructured":"National Organization for Rare Disorders Inc. NORD\u00ae Rare Disease Database [Internet]. 2024. https:\/\/rarediseases.org\/?s=Huntington%27s+Disease+*&rdb-search=true&post_type%5B%5D=rare-diseases&post_type%5B%5D=gard-rare-disease"},{"key":"668_CR19","unstructured":"Ellis AG, Mickle K. Spinraza \u00ae and Zolgensma\u00ae for spinal muscular atrophy: effectiveness and value: final evidence report. Inst Clin Econ Rev. 2019."},{"key":"668_CR20","unstructured":"Institute for Clinical and Economic Review. Modifications to the ICER value assessment framework for treatments for ultra-rare diseases. 2017;15. https:\/\/icer-review.org\/"},{"key":"668_CR21","doi-asserted-by":"publisher","unstructured":"Dean R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Heal Policy [Internet]. 2021. https:\/\/doi.org\/10.1080\/20016689.2021.1889841","DOI":"10.1080\/20016689.2021.1889841"},{"key":"668_CR22","unstructured":"Biogen. SPINRAZA\u00ae (nusinersen) [Internet]. Spinraza.com. 2018. https:\/\/www.spinraza.com\/"},{"key":"668_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","volume":"18","author":"P Thokala","year":"2020","unstructured":"Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc [Internet]. 2020;18:41. https:\/\/doi.org\/10.1186\/s12962-020-00234-8.","journal-title":"Cost Eff Resour Alloc [Internet]."},{"key":"668_CR24","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1089\/hum.2022.054","volume":"33","author":"B Stolte","year":"2022","unstructured":"Stolte B, Schreiber-Katz O, G\u00fcnther R, Wurster CD, Petri S, Osmanovic A, et al. Prevalence of anti-adeno-associated virus serotype 9 antibodies in adult patients with spinal muscular atrophy. Hum Gene Ther [Internet]. 2022;33:968\u201376. https:\/\/doi.org\/10.1089\/hum.2022.054.","journal-title":"Hum Gene Ther [Internet]."},{"key":"668_CR25","unstructured":"MD Save Inc. Stereotactic radiosurgery (SRS) treatment delivery [Internet]. 2021. https:\/\/www.mdsave.com\/procedures\/stereotactic-radiosurgery-srs-treatment-delivery\/d280f8ca"},{"key":"668_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","volume":"23","author":"M Droege","year":"2020","unstructured":"Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ [Internet]. 2020;23:70\u20139. https:\/\/doi.org\/10.1080\/13696998.2019.1646263.","journal-title":"J Med Econ [Internet]."},{"key":"668_CR27","doi-asserted-by":"crossref","unstructured":"Fernandez M, Hogue SL, Preblick R, Kwong WJ. Review of the cost of venous thromboembolism. Clin Outcomes Res [Internet]. 2015;7:451. http:\/\/www.dovepress.com\/review-of-the-cost-of-venous-thromboembolism-peer-reviewed-article-CEOR","DOI":"10.2147\/CEOR.S85635"},{"key":"668_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1176\/appi.psy.42.1.68","volume":"42","author":"K Franco","year":"2001","unstructured":"Franco K, Litaker D, Locala J, Bronson D. The cost of delirium in the surgical patient. Psychosomatics [Internet]. 2001;42:68\u201373.","journal-title":"Psychosomatics [Internet]."},{"key":"668_CR29","doi-asserted-by":"crossref","unstructured":"MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Heal Pharm [Internet]. 2006;63:S5\u201315. https:\/\/academic.oup.com\/ajhp\/article\/63\/20_Supplement_6\/S5\/5134711","DOI":"10.2146\/ajhp060388"},{"key":"668_CR30","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s10198-019-01092-9","volume":"20","author":"A Hawton","year":"2019","unstructured":"Hawton A, Green C, Goodwin E, Harrower T. Health state utility values (QALY weights) for Huntington\u2019s disease: an analysis of data from the European Huntington\u2019s Disease Network (EHDN). Eur J Heal Econ [Internet]. 2019;20:1335\u201347. https:\/\/doi.org\/10.1007\/s10198-019-01092-9.","journal-title":"Eur J Heal Econ [Internet]."},{"key":"668_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1477-7525-8-50","volume":"8","author":"KM Beusterien","year":"2010","unstructured":"Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O\u2019Toole A, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes [Internet]. 2010;8:50. https:\/\/doi.org\/10.1186\/1477-7525-8-50.","journal-title":"Health Qual Life Outcomes [Internet]."},{"key":"668_CR32","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jval.2021.04.1284","volume":"24","author":"SD Reed","year":"2021","unstructured":"Reed SD, Yang J-C, Gonzalez JM, Johnson FR. Quantifying value of hope. Value Heal [Internet]. 2021;24:1511\u20139.","journal-title":"Value Heal [Internet]."},{"key":"668_CR33","doi-asserted-by":"publisher","unstructured":"Garrison LP, Zamora B, Li M, Towse A. Augmenting cost-effectiveness analysis for uncertainty: the implications for value assessment\u2014Rationale and empirical support. J Manag Care Spec Pharm [Internet]. 2020;26:400\u20136. https:\/\/doi.org\/10.18553\/jmcp.2020.26.4.400","DOI":"10.18553\/jmcp.2020.26.4.400"},{"key":"668_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25(1)","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement : Updated reporting guidance for health economic evaluations. Value Heal [Internet]. 2022; 25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","journal-title":"Value Heal [Internet]."},{"key":"668_CR35","unstructured":"Arias E, Xu J. United States Life Tables, 2020. National Vital Statistics Reports, National Center for Health Statistics. https:\/\/stacks.cdc.gov\/view\/cdc\/118055"},{"key":"668_CR36","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/13696998.2021.2002579","volume":"24","author":"A Exuzides","year":"2021","unstructured":"Exuzides A, Reddy SR, Chang E, Ta JT, Patel AM, Paydar C, et al. Healthcare utilization and cost burden of Huntington\u2019s disease among Medicare beneficiaries in the United States. J Med Econ [Internet]. 2021;24:1327\u201336. https:\/\/doi.org\/10.1080\/13696998.2021.2002579.","journal-title":"J Med Econ [Internet]."},{"key":"668_CR37","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/ene.13107","volume":"23","author":"C Jones","year":"2016","unstructured":"Jones C, Busse M, Quinn L, Dawes H, Drew C, Kelson M, et al. The societal cost of Huntington\u2019s disease: are we underestimating the burden? Eur J Neurol [Internet]. 2016;23:1588\u201390. https:\/\/doi.org\/10.1111\/ene.13107.","journal-title":"Eur J Neurol [Internet]."},{"key":"668_CR38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/13696998.2023.2222561","volume":"26","author":"AM Patel","year":"2023","unstructured":"Patel AM, Chang E, Paydar C, Reddy SR. Healthcare utilization and direct medical costs of Huntington\u2019s disease among Medicaid beneficiaries in the United States. J Med Econ [Internet]. 2023;26:811\u201320. https:\/\/doi.org\/10.1080\/13696998.2023.2222561.","journal-title":"J Med Econ [Internet]."},{"key":"668_CR39","doi-asserted-by":"publisher","unstructured":"Silva-Paredes G, Urbanos-Garrido RM, Inca-Martinez M, Rabinowitz D, Cornejo-Olivas MR. Economic burden of Huntington\u2019s disease in Peru. BMC Health Serv Res [Internet]. 2019;19:1017. https:\/\/doi.org\/10.1186\/s12913-019-4806-6","DOI":"10.1186\/s12913-019-4806-6"},{"key":"668_CR40","unstructured":"Hdyo\/Roche. An update on dosing for GENERATION HD2. [Internet]. [cited 28 April 2026]. https:\/\/www.hdyo.org\/a\/852-an-update-on-dosing-for-generation-hd2"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00668-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00668-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00668-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:13:02Z","timestamp":1789992782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00668-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00668-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. Joseph Mattingly II reports unrelated research funding from the Alzheimer\u2019s Association and unrelated consulting fees from Arnold Ventures, Pharmaceutical Research and Manufacturers of America, and the Pharmaceutical Care Management Association. T. Joseph Mattingly II is an editorial board member of\n                      PharmacoEconomics\n                      -\n                      Open\n                      . T. Joseph Mattingly II was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Julia F. Slejko reports unrelated funding from PhRMA Foundation, AstraZeneca, and Genentech, Inc.; and consulting for Boehringer Ingelheim, Merck, and Teva Pharmaceuticals for work unrelated to the research presented in this paper. Joseph M. Savitt, MD, PhD has no competing interests to declare that are relevant to the content of this article. Divya Patil, MS, has no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}